Detall de la convocatòria

Característiques

Característica
Objectiu de la convocatòria
The Alzheimer's Drug Discovery Foundation (ADDF) funds drug discovery and development research programs in the field of Alzheimer's disease (AD), related dementias and cognitive aging. The ADDF seeks to fill the critical translational funding gap between basic research and later stage drug development by funding promising drug discovery and development programs. In addition to funding academic programs, the ADDF also invests in and creates early stage biotechnology companies. The ADDF also co-sponsors conferences to stimulate new ideas and approaches in areas of interest to the Foundation.
Característiques principals
Programs areas of particular interest include:
  • Repurposing – Testing drugs approved for other indications in Alzheimer’s disease clinical trials. Proposals should be hypothesis driven and drugs chosen for testing should target a mechanism of action(s) common to both diseases.
  • Therapies addressing the following targets: Energy utilization/mitochondria function, insulin sensitivity, protein degradation/autophagy, ApoE function and cholesterol metabolism, vesicular trafficking, inflammatory pathways, synaptic function/morphology, calcium regulation, myelin changes, ischemia and oxidative stress, vascular injury and the blood-brain barrier interface.

    FUNDING MECHANISMS
  • Academic Program seeks to create and support innovative translational programs in academic medical centers and universities.
  • Biotechnology Development Program supports qualified scientific projects in existing, private, early-stage biotechnology companies. The ADDF will provide support for qualified projects in more advanced companies if a clear need for non-profit funding to support the project can be demonstrated and justified. Funding is typically made as a program-related investment.
  • Biotechnology Founders Technology Transfer Program supports academic programs that are eligible for technology transfer and the start-up of new biotechnology companies. Up to 35% of funds from these awards may be employed for expenses related to company formation, such as administrative, legal, patent and third-party vendor costs.
    • Lloc de presentació
    El personal de l'IMIM i PSMAR que necessiteu més informació adreceu-vos a:
    Servei de Recerca. C/ Doctor Aiguader, 88. 08003-Barcelona. Tel.: 93.316.05.76.
    Marta López: mlopez4@imim.es Ext.: 1576
    Carol Barnwell: cbarnwell@imim.es Ext.: 1670
    Convocatòria (URL)
    Convocatòria:
    http://www.alzdiscovery.org/assets/content/static/2014_PACT_RFP.pdf
    Instruccions:
    http://www.alzdiscovery.org/assets/content/static/ADDF_APPLICATION_FORM_FINAL_July2013.pdf
    Dotació
    $ 1,500,000
    Durada
    Multi-year proposals will be considered.
    AVÍS IMPORTANT
    2014 QUARTERLY DEADLINES
    March 5
    June 5
    September 5
    December 5

    Interested applicants must first submit a Letter of Intent electronically via the ADDF website (www.alzdiscovery.org) before the deadline.

    Arxius

    Arxiu